On November 5, ST Wanbang announced that the WP107 multi-dose climbing clinical study completed and the first team joined the team. WP107 is a novel oral solution dosage form independently developed by the company's innovative drug research and development team based on existing clinical data for Huperzine A injection. It is a double reported variety between China and the US. The project has been certified as an orphan drug by the US FDA and approved by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Yuying Children's Hospital Affiliated to Wenzhou Medical University. The completion of the first domestic team joining the group is another step forward in this international development chain.
Zhitongcaijing · 2d ago
Share
Listen to the news
On November 5, ST Wanbang announced that the WP107 multi-dose climbing clinical study completed and the first team joined the team. WP107 is a novel oral solution dosage form independently developed by the company's innovative drug research and development team based on existing clinical data for Huperzine A injection. It is a double reported variety between China and the US. The project has been certified as an orphan drug by the US FDA and approved by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Yuying Children's Hospital Affiliated to Wenzhou Medical University. The completion of the first domestic team joining the group is another step forward in this international development chain.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending